01 May 2022 : Clinical Research
Association Between Thromboelastography and Coronary Heart Disease
Liuqiao Yang123ACDEF, Lei Ruan4ABD, Yanping ZhaoDOI: 10.12659/MSM.935340
Med Sci Monit 2022; 28:e935340
Table 1 Basic characteristics of study participants.
| Controls (n=68) | CHD (n=49) | Ischemic stroke (n=34) | |
|---|---|---|---|
| Age (years) | 61.4±9.4 | 60.5±9.6 | 63.2±9.8 |
| Male (%) | 51 (75.0%) | 36 (73.5%) | 27 (79.4%) |
| Current smoker (%) | 15 (22.1%) | 15 (30.6%) | 12 (35.3%) |
| BMI (kg/m) | 25.0±3.3 | 25.6±3.3 | 25.2±2.5 |
| Medical history | |||
| Diabetes mellitus (%) | 18 (26.5%) | 8 (16.3%) | 11 (32.4%) |
| Hypertension (%) | 46 (67.6%) | 32 (65.3%) | 21 (61.8%) |
| Medication history | |||
| Antiplatelet drug (%) | 15 (22.1%) | 19 (38.8%) | 4 (11.8%) |
| Lipid-lowering drug (%) | 26 (38.2%) | 25 (51.0%) | 11 (32.4%) |
| Routine laboratory test | |||
| ESR (mm/h) | 5.0 (2.0, 7.2) | 4.0 (2.0, 7.0) | 4.5 (2.0, 10.0) |
| Hemoglobin (g/L) | 150.5 (142.0, 156.2) | 148.0 (138.0, 157.0) | 147.5 (140.2, 157.5) |
| WBC count (10/L) | 5.5 (4.8, 6.3) | 6.0 (4.9, 6.7) | 5.7 (4.7, 6.9) |
| HDL-C (mmol/L) | 1.1 (1.0, 1.3) | 1.1 (1.0, 1.2) | 1.2 (1.0, 1.4) |
| LDL-C (mmol/L) | 2.6±0.8 | 2.3±0.8* | 2.9±1.3 |
| Total cholesterol (mmol/L) | 4.4±0.9 | 3.8±0.9* | 4.5±1.4 |
| Triglyceride (mmol/L) | 1.5 (1.2, 2.2) | 1.2 (0.9, 1.7)* | 1.4 (1.0, 2.2) |
| Platelet parameters | |||
| Platelet count (10/L) | 212.2±54.6 | 213.2±49.2 | 207.1±49.7 |
| Mean platelet volume (fL) | 11.0±0.9 | 10.9±0.9 | 10.8±1.0 |
| Platelet volume distribution width (fL) | 13.5±2.1 | 13.3±2.0 | 13.2±2.5 |
| Platelet hematocrit (%) | 0.2±0.1 | 0.2±0.0 | 0.2±0.0 |
| Continuous variables were described as mean±standard deviation or median (interquartile range) and categorical variables were presented as (percentages). BMI – body mass index; CHD – coronary heart disease; ESR – erythrocyte sedimentation rate; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; WBC – white blood cell. * | |||






